Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of combining bortezomib
(Velcade) with rituximab, fludarabine, mitoxantrone, and dexamethasone in treating patients
with follicular cell lymphoma.